• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About > Annual reports
2021
Annual Report
unlocking the promise of medical innovation for all
2021 ANNUAL REPORT
2021 FINANCIAL REPORT​
Home > About > Annual reports
2021
Annual Report
unlocking the promise of medical innovation for all
2021 ANNUAL REPORT
2021 FINANCIAL REPORT​
  • Foreword
  • 2021 in numbers
  • Commitments
  • Features
  • Research worldwide
  • Our progress
  • R&D portfolio
  • Partners
  • Finances

Foreword

'Though the COVID-19 pandemic continued to take a devastating toll in 2021, we advanced 50 projects in our research and development portfolio, including multiple new chemical entities, delivered new treatments, and forged new alliances for innovation.'

Dr Marie-Paule Kieny, Chair of the Board of Directors &
Dr Bernard Pécoul, Executive Director

READ MORE

2021 in numbers

R&D portfolio

41 R&D projects and an additional
9 projects in the access phase

Clinical trials

27 clinical trials in 8 disease areas at 88 sites in 28 countries

Fostering sustainable solutions

80% of all R&D partner FTEs* are based in low-and-middle-income countries
*Staff in full-time equivalents

FINANCES

EUR 66 M in annual expenditure,
89% of which on our social mission

DISCOVER MORE

Our cross-cutting commitments

DNDi’s 2021-2028 strategic plan charts our path to deliver 25 new treatments for neglected patients in our first 25 years. Learn more about the strategic imperatives shaping our work to end the neglect.

Innovating for children's health
Advancing gender equity and gender-responsive R&D
Confronting climate-sensitive diseases and reducing our carbon footprint
Harnessing AI and new technologies to meet neglected patients’ needs

Features

Take a tour of highlights of the year from our teams and partners in Africa, Asia, and Latin America.

Africa

Clinical trial capacity where it’s needed most

READ

Data for good: Eastern Africa innovation

READ

Cynthia’s story

READ
Clinical trial capacity where it’s needed most
'We have been active in clinical trials for the past 10 years and we are very proud of our work.'
Principal Investigator Dr Felix Akwaso in front of the new river blindness ward at Masi-Manimba Hospital, DRC
Data for good: Eastern Africa innovation

DNDi’s Data Management and Biostatistics Centre in Nairobi, Kenya has helped to maximize clinical research capacity in Africa since 2004.

'I wouldn’t be alive today if it wasn’t for the treatment. I am so grateful for it.'
Cynthia Metuso lives in New Crossroads, Cape Town, South Africa. When she contracted cryptococcal meningitis, she was convinced she was going to die. But with the help of life-saving treatment, Cynthia has made a full recovery.
Asia

Driving innovation through South-South collaboration

READ

Paving the way for the elimination of visceral leishmaniasis in India

READ
Driving innovation through South-South collaboration

Leveraging our experience bolstering South-South collaboration for hepatitis C R&D, we are now joining essential government, science, and industry partners across LMICs to find a safe, effective, and affordable treatment for dengue fever.

Paving the way for the elimination of visceral leishmaniasis in India

Since the start of intensified VL detection and treatment activities in India, VL cases have plummeted by 98%, from 77,100 registered cases in 1992 to just 1,275 in 2021. However, the ‘last mile’ of India’s push toward VL elimination presents unique challenges, as will sustaining elimination, once achieved.

Lalmati Devi, 45 years old, lives in Bheldi, Bihar, India.
Latin America
Screenshot of iChagas app

Focusing on the needs of the most neglected

READ

Drug discovery: New partnership for COVID-19 antivirals

READ

Expediting access: The iChagas app

READ
Focusing on the needs of the most neglected
'There are 20 days of treatment, and if you miss one, the countdown starts again.'
Ana Mariluz Reyes Morales and her family lives in Ancas, a small town in southern Peru. Both of her two children have CL, and the hospital where they receive care in Lima is 12 hours away from their home.
Drug discovery: New partnership for COVID-19 antivirals

At the end of 2021, DNDi, the University of São Paulo, and Medicines for Malaria Venture (MMV) joined forces to identify and develop new lead molecules targeting SARS-CoV-2 that can be advanced to clinical trials for new safe, effective, and affordable antiviral treatments for COVID-19.

Expediting access: The iChagas app

Health workers often lack access to the information they need to identify and care for people with Chagas. To help overcome this barrier, DNDi launched the mobile application iChagas in 2021, developed with partners across the region. 

DNDi research worldwide

Early-stage research and clinical development in 2021

88 clinical sites in 28 countries, active
in 8 disease areas
64 clinicalearly-stage research sites in 16 countries
3,487 patients enrolled in active DNDi
clinical studies

Active clinical sites

  • Sleeping sickness
  • Leishmaniasis
  • Chagas disease
  • Filaria: River blindness
  • Mycetoma
  • HIV
  • Hepatitis C
  • COVID-19

EARLY-STAGE RESEARCH SITES

(Drug discovery and pre-clinical development)

RESEARCH PLATFORMS AND NETWORKS


Map boundaries and borders do not reflect any position by DNDi on their legal status
FIND OUT MORE

Our progress in 2021

Sleeping sickness

Delivering breakthrough treatments and expediting access for sustained elimination

Read more

Leishmaniasis

Delivering safer, simpler treatments to save lives and reduce social stigma

Read more

Chagas disease

Searching for shorter, safer, more effective treatments for a silent killer

Read more

Filaria

Developing a rapid cure for millions at risk

Read more

Mycetoma

Conducting the world’s first clinical trial

Read more

HIV

Ensuring access to life-saving treatment for children and people with advanced HIV

Read more

Hepatitis C

Accelerating access to affordable treatments and supporting global elimination efforts

Read more

COVID-19

Accelerating research, advocating for equity, and preparing for future pandemics

Read more

From bench to bedside

DNDi research & development portfolio

DNDi Portfolio June 2021

Acting as a ‘conductor of a virtual orchestra’, we collaborate with research partners around the world at all stages of the R&D process. Our R&D portfolio includes 49 projects and 20 new chemical entities for 9 disease areas.

EXPLORE PORTFOLIO

Partners

LEARN MORE

Finances

LEARN MORE

Photo credits: Brent Stirton/Getty Images; Manon Voland-DNDi; Kishore Pandit-DNDi; Sydelle Willow Smith-EDCTP; Vinicius Berger-DNDi; DeepMind; Karin Schermbrucker-DNDi; Black Visuals-DNDi; Manis Gupta-DNDi; Ana Ferreira-DNDi; Emmanuel Museruka-DNDi; Ley Uwera-DNDi; Lameck Ododo-DNDi; Xavier Vahed-DNDi; Abang Amirrul Hadi-DNDi; Maneesh Agnihotri-DNDi

A word of thanks

DNDi has now delivered 12 new treatments for six neglected diseases.

Every contribution is essential to advancing DNDi’s mission and goals. We are deeply grateful to our donors and partners for their support in 2021.

OUR DONORS
OUR PARTNERS

How we use the money

general management
0 %
social mission
0 %
fundraising
0 %
DONATE

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License